A gene editing strategy for refractory CFTR mutations causing cystic fibrosis.

The goal of our project is to develop CRISPR-Cas gene editing therapy for CFTR mutations refractory to current CFTR modulators. A functional rescue will be assessed in human CF intestinal organoïds and airway cultures.